MoonLake Immunotherapeutics (MLTX) Assets Average (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Assets Average of $412.4 million for Q1 2026, down 16.62% year-over-year from $494.6 million in Q1 2025, and down 1.66% quarter-over-quarter from $419.4 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Assets Average (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $412.4 million for Q1 2026.
- In Q1 2026, Assets Average fell 16.62% year-over-year to $412.4 million; the TTM figure through Mar 2026 stood at $412.4 million (down 16.62% YoY), while the FY2025 annual figure was $451.2 million, down 10.17% from the prior year.
- Assets Average for Q1 2026 stood at $412.4 million, down from $419.4 million in the prior quarter.
- The five-year high for Assets Average was $554.5 million in Q2 2024, with the low at $71.8 million in Q1 2023.
- The 5-year median for Assets Average is $437.2 million (2025), against an average of $365.6 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average plunged 40.37% in 2023, then soared 659.3% in 2024.
- MoonLake Immunotherapeutics' Assets Average stood at $82.7 million in 2022, then surged by 520.64% to $513.4 million in 2023, then slipped by 2.98% to $498.1 million in 2024, then slipped by 15.8% to $419.4 million in 2025, then dropped by 1.66% to $412.4 million in 2026.
- Business Quant data shows MLTX's Assets Average at $412.4 million in Q1 2026, $419.4 million in Q4 2025, and $437.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 487.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 487.16 Mn |
| Mar 31, 2026 | 412.40 Mn |
| Dec 31, 2025 | 419.38 Mn |
| Sep 30, 2025 | 437.22 Mn |
| Jun 30, 2025 | 485.68 Mn |
| Mar 31, 2025 | 494.60 Mn |
| Dec 31, 2024 | 498.07 Mn |
| Sep 30, 2024 | 531.55 Mn |
| Jun 30, 2024 | 554.50 Mn |
| Mar 31, 2024 | 545.33 Mn |
| Dec 31, 2023 | 513.38 Mn |
| Sep 30, 2023 | 503.42 Mn |
| Jun 30, 2023 | 286.71 Mn |
| Mar 31, 2023 | 71.82 Mn |
| Dec 31, 2022 | 82.72 Mn |
| Sep 30, 2022 | 93.51 Mn |
| Jun 30, 2022 | 164.82 Mn |
| Mar 31, 2022 | 120.45 Mn |
| Dec 31, 2021 | 62.96 Mn |
| Sep 30, 2021 | 116.31 Mn |